Literature DB >> 7759949

Structure-activity relationships of chemokines.

I Clark-Lewis1, K S Kim, K Rajarathnam, J H Gong, B Dewald, B Moser, M Baggiolini, B D Sykes.   

Abstract

Structural analysis of chemokines has revealed that the alpha/beta structural-fold is highly conserved among both the CXC and CC chemokine classes. Although dimerization and aggregation is often observed, the chemokines function as monomers. The critical receptor binding regions are in the NH2-terminal 20 residues of the protein and are the least ordered in solution. The flexible NH2-terminal region is the most critical receptor binding site and a second site also exists in the loop that follows the two disulfides. The well-ordered regions are not directly involved in receptor binding but, along with the disulfides, they provide a scaffold that determines the conformation of the sites that are critical for receptor binding. These general requirements for function are common to all the chemokines. For the CC chemokines, receptor activation and receptor binding regions are separate within the 10 residue NH2-terminal region. This has allowed identification of high affinity analogs that do not activate the receptor and are potent antagonists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759949     DOI: 10.1002/jlb.57.5.703

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  87 in total

1.  Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus.

Authors:  A Carfí; C A Smith; P J Smolak; J McGrew; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

3.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Functional characterization of the C---C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2.

Authors:  M D Krathwohl; R Hromas; D R Brown; H E Broxmeyer; K H Fife
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 6.  CXCL12 signaling in the development of the nervous system.

Authors:  Divakar S Mithal; Ghazal Banisadr; Richard J Miller
Journal:  J Neuroimmune Pharmacol       Date:  2012-01-21       Impact factor: 4.147

7.  The solution structure of the anti-HIV chemokine vMIP-II.

Authors:  A C Liwang; Z X Wang; Y Sun; S C Peiper; P J Liwang
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

8.  Blasts from the past.

Authors:  Paul A Insel; Stuart Kornfeld; Philip W Majerus; Andrew R Marks; Paul A Marks; Arnold S Relman; Bruce F Scharschmidt; Thomas P Stossel; Ajit P Varki; Stephen J Weiss; Jean D Wilson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 9.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

10.  Control of feeding behavior in C. elegans by human G protein-coupled receptors permits screening for agonist-expressing bacteria.

Authors:  Michelle S Teng; Paul Shadbolt; Andrew G Fraser; Gert Jansen; John McCafferty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.